Form 8-K - Current report:
SEC Accession No. 0001104659-25-029608
Filing Date
2025-03-31
Accepted
2025-03-31 07:10:25
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510890d2_8k.htm   iXBRL 8-K 24792
2 EXHIBIT 99.1 tm2510890d2_ex99-1.htm EX-99.1 66156
6 GRAPHIC tm2510890d2_ex99-1img01.jpg GRAPHIC 9271
  Complete submission text file 0001104659-25-029608.txt   287740

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20250331.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20250331_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20250331_pre.xml EX-101.PRE 22373
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2510890d2_8k_htm.xml XML 3691
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 25788824
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)